

**HPTN 094 – INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care**  
**LIVE Open Report – December 3, 2025**  
**Visit Cutoff Date: December 3, 2025**  
**Table O5a – Visit Completion <sup>1</sup> Summary by Site: HIV+**

	<b>Overall</b>	<b>New York – Bronx Prevention</b>	<b>Los Angeles – Vine Street</b>	<b>Washington DC – Washington Circle</b>	<b>Houston AIDS Research Team CRS</b>	<b>Philadelphia</b>
Total Participants Enrolled	38	12	2	6	7	11
Terminated Prior to Week 26 Visit <sup>2</sup>	1/38 (2.6%)	1/12 (8.3%)	0/2 (0.0%)	0/6 (0.0%)	0/7 (0.0%)	0/11 (0.0%)
Total Participants Expected for Week 26	37	11	2	6	7	11
Completed the Week 26 Visit (Total) <sup>3</sup>	32/37 (86.5%)	7/11 (63.6%)	2/2 (100.0%)	6/6 (100.0%)	7/7 (100.0%)	10/11 (90.9%)
In Target Visit Window <sup>4</sup>	24/37 (64.9%)	4/11 (36.4%)	2/2 (100.0%)	5/6 (83.3%)	5/7 (71.4%)	8/11 (72.7%)
In Allowable Visit Window <sup>5</sup>	32/37 (86.5%)	7/11 (63.6%)	2/2 (100.0%)	6/6 (100.0%)	7/7 (100.0%)	10/11 (90.9%)
Terminated Prior to Week 52 Visit <sup>2</sup>	9/38 (23.7%)	5/12 (41.7%)	0/2 (0.0%)	1/6 (16.7%)	2/7 (28.6%)	1/11 (9.1%)
Total Participants Expected for Week 52	29	7	2	5	5	10
Completed the Week 52 Visit (Total) <sup>3</sup>	29/29 (100.0%)	7/7 (100.0%)	2/2 (100.0%)	5/5 (100.0%)	5/5 (100.0%)	10/10 (100.0%)
In Target Visit Window <sup>4</sup>	22/29 (75.9%)	5/7 (71.4%)	2/2 (100.0%)	5/5 (100.0%)	3/5 (60.0%)	7/10 (70.0%)
In Allowable Visit Window <sup>5</sup>	29/29 (100.0%)	7/7 (100.0%)	2/2 (100.0%)	5/5 (100.0%)	5/5 (100.0%)	10/10 (100.0%)
Participants pending study completion <sup>6</sup>	0/29 (0.0%)	0/7 (0.0%)	0/2 (0.0%)	0/5 (0.0%)	0/5 (0.0%)	0/10 (0.0%)

<sup>1</sup> Visit Completion at a visit is defined as the number (and %) of participants who completed the visit divided by the number of participants who are expected (target visit window has closed), plus any participants who completed the visit prior to their target window closure. Participants who terminated from the study prior to the visit are not expected.

<sup>2</sup> Week 52 visit includes participants who terminated prior to the Week 26 visit.

<sup>3</sup> The total is not the sum of participants in target visit window and allowable visit window because (a) visits within the target window are also within the allowable window, and (b) some participants may have completed the visit outside both windows.

<sup>4</sup> The Week 26 Target visit window is between 168 and 210 days from enrollment, and the Week 52 Target visit window is between 351 and 393 days from enrollment.

<sup>5</sup> The Week 26 Allowable visit window is between 126 and 308 days from enrollment, and the Week 52 Allowable visit window is between day 309 – 449 days from enrollment.

<sup>6</sup> All participants who have not completed the Week 52 visit and not terminated from the study.

**HPTN 094 – INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care**  
**LIVE Open Report – December 3, 2025**  
**Visit Cutoff Date: December 3, 2025**  
**Table O5b – Visit Completion <sup>1</sup> Summary by Site: HIV–**

	<b>Overall</b>	<b>New York – Bronx Prevention</b>	<b>Los Angeles – Vine Street</b>	<b>Washington DC – Washington Circle</b>	<b>Houston AIDS Research Team CRS</b>	<b>Philadelphia</b>
Total Participants Enrolled	409	82	93	35	97	102
Terminated Prior to Week 26 Visit <sup>2</sup>	11/409 (2.7%)	1/82 (1.2%)	3/93 (3.2%)	1/35 (2.9%)	5/97 (5.2%)	1/102 (1.0%)
Total Participants Expected for Week 26	398	81	90	34	92	101
Completed the Week 26 Visit (Total) <sup>3</sup>	324/398 (81.4%)	58/81 (71.6%)	81/90 (90.0%)	30/34 (88.2%)	78/92 (84.8%)	77/101 (76.2%)
In Target Visit Window <sup>4</sup>	218/398 (54.8%)	34/81 (42.0%)	64/90 (71.1%)	19/34 (55.9%)	46/92 (50.0%)	55/101 (54.5%)
In Allowable Visit Window <sup>5</sup>	323/398 (81.2%)	58/81 (71.6%)	80/90 (88.9%)	30/34 (88.2%)	78/92 (84.8%)	77/101 (76.2%)
Terminated Prior to Week 52 Visit <sup>2</sup>	92/409 (22.5%)	31/82 (37.8%)	15/93 (16.1%)	8/35 (22.9%)	24/97 (24.7%)	14/102 (13.7%)
Total Participants Expected for Week 52	317	51	78	27	73	88
Completed the Week 52 Visit (Total) <sup>3</sup>	317/317 (100.0%)	51/51 (100.0%)	78/78 (100.0%)	27/27 (100.0%)	73/73 (100.0%)	88/88 (100.0%)
In Target Visit Window <sup>4</sup>	196/317 (61.8%)	15/51 (29.4%)	62/78 (79.5%)	24/27 (88.9%)	42/73 (57.5%)	53/88 (60.2%)
In Allowable Visit Window <sup>5</sup>	304/317 (95.9%)	48/51 (94.1%)	76/78 (97.4%)	27/27 (100.0%)	73/73 (100.0%)	80/88 (90.9%)
Participants pending study completion <sup>6</sup>	0/317 (0.0%)	0/51 (0.0%)	0/78 (0.0%)	0/27 (0.0%)	0/73 (0.0%)	0/88 (0.0%)

<sup>1</sup> Visit Completion at a visit is defined as the number (and %) of participants who completed the visit divided by the number of participants who are expected (target visit window has closed), plus any participants who completed the visit prior to their target window closure. Participants who terminated from the study prior to the visit are not expected.

<sup>2</sup> Week 52 visit includes participants who terminated prior to the Week 26 visit.

<sup>3</sup> The total is not the sum of participants in target visit window and allowable visit window because (a) visits within the target window are also within the allowable window, and (b) some participants may have completed the visit outside both windows.

<sup>4</sup> The Week 26 Target visit window is between 168 and 210 days from enrollment, and the Week 52 Target visit window is between 351 and 393 days from enrollment.

<sup>5</sup> The Week 26 Allowable visit window is between 126 and 308 days from enrollment, and the Week 52 Allowable visit window is between day 309 – 449 days from enrollment.

<sup>6</sup> All participants who have not completed the Week 52 visit and not terminated from the study.

**HPTN 094 – INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care**  
**LIVE Open Report – December 3, 2025**  
**Visit Cutoff Date: December 3, 2025**  
**Table O5c – Visit Completion <sup>1</sup> Summary by HIV Status**

	Overall	HIV+	HIV-
Total Participants Enrolled	447	38	409
Terminated Prior to Week 26 Visit <sup>2</sup>	12/447 (2.7%)	1/38 (2.6%)	11/409 (2.7%)
Total Participants Expected for Week 26	435	37	398
Completed the Week 26 Visit (Total) <sup>3</sup>	356/435 (81.8%)	32/37 (86.5%)	324/398 (81.4%)
In Target Visit Window <sup>4</sup>	242/435 (55.6%)	24/37 (64.9%)	218/398 (54.8%)
In Allowable Visit Window <sup>5</sup>	355/435 (81.6%)	32/37 (86.5%)	323/398 (81.2%)
Terminated Prior to Week 52 Visit <sup>2</sup>	101/447 (22.6%)	9/38 (23.7%)	92/409 (22.5%)
Total Participants Expected for Week 52	346	29	317
Completed the Week 52 Visit (Total) <sup>3</sup>	346/346 (100.0%)	29/29 (100.0%)	317/317 (100.0%)
In Target Visit Window <sup>4</sup>	218/346 (63.0%)	22/29 (75.9%)	196/317 (61.8%)
In Allowable Visit Window <sup>5</sup>	333/346 (96.2%)	29/29 (100.0%)	304/317 (95.9%)
Participants pending study completion <sup>6</sup>	0/346 (0.0%)	0/29 (0.0%)	0/317 (0.0%)

<sup>1</sup> Visit Completion at a visit is defined as the number (and %) of participants who completed the visit divided by the number of participants who are expected (target visit window has closed), plus any participants who completed the visit prior to their target window closure. Participants who terminated from the study prior to the visit are not expected.

<sup>2</sup> Week 52 visit includes participants who terminated prior to the Week 26 visit.

<sup>3</sup> The total is not the sum of participants in target visit window and allowable visit window because (a) visits within the target window are also within the allowable window, and (b) some participants may have completed the visit outside both windows.

<sup>4</sup> The Week 26 Target visit window is between 168 and 210 days from enrollment, and the Week 52 Target visit window is between 351 and 393 days from enrollment.

<sup>5</sup> The Week 26 Allowable visit window is between 126 and 308 days from enrollment, and the Week 52 Allowable visit window is between day 309 – 449 days from enrollment.

<sup>6</sup> All participants who have not completed the Week 52 visit and not terminated from the study.